179 related articles for article (PubMed ID: 34042306)
1. Incident Rheumatoid Arthritis in HIV Infection: Epidemiology and Treatment.
Hanberg JS; Hsieh E; Akgün KM; Weinstein E; Fraenkel L; Justice AC;
Arthritis Rheumatol; 2021 Dec; 73(12):2189-2199. PubMed ID: 34042306
[TBL] [Abstract][Full Text] [Related]
2. A systematic review of validated methods for identifying patients with rheumatoid arthritis using administrative or claims data.
Chung CP; Rohan P; Krishnaswami S; McPheeters ML
Vaccine; 2013 Dec; 31 Suppl 10():K41-61. PubMed ID: 24331074
[TBL] [Abstract][Full Text] [Related]
3. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
[TBL] [Abstract][Full Text] [Related]
4. Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.
Betts KA; Griffith J; Ganguli A; Li N; Douglas K; Wu EQ
Clin Ther; 2016 May; 38(5):1205-16. PubMed ID: 27045991
[TBL] [Abstract][Full Text] [Related]
5. Prospective cohort study of effects of infliximab on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis.
Bruns A; Nicaise-Roland P; Hayem G; Palazzo E; Dieudé P; Grootenboer-Mignot S; Chollet-Martin S; Meyer O
Joint Bone Spine; 2009 May; 76(3):248-53. PubMed ID: 19208451
[TBL] [Abstract][Full Text] [Related]
6. Early Remission Is a Realistic Target in a Majority of Patients with DMARD-naive Rheumatoid Arthritis.
Rannio T; Asikainen J; Kokko A; Hannonen P; Sokka T
J Rheumatol; 2016 Apr; 43(4):699-706. PubMed ID: 26879355
[TBL] [Abstract][Full Text] [Related]
7. Does immunological remission, defined as disappearance of autoantibodies, occur with current treatment strategies? A long-term follow-up study in rheumatoid arthritis patients who achieved sustained DMARD-free status.
Boeters DM; Burgers LE; Toes RE; van der Helm-van Mil A
Ann Rheum Dis; 2019 Nov; 78(11):1497-1504. PubMed ID: 31413004
[TBL] [Abstract][Full Text] [Related]
8. Autoantibody Seropositivity and Risk for Interstitial Lung Disease in a Prospective Male-Predominant Rheumatoid Arthritis Cohort of U.S. Veterans.
Natalini JG; Baker JF; Singh N; Mahajan TD; Roul P; Thiele GM; Sauer BC; Johnson CR; Kawut SM; Mikuls TR; England BR
Ann Am Thorac Soc; 2021 Apr; 18(4):598-605. PubMed ID: 33026891
[No Abstract] [Full Text] [Related]
9. Association of Seropositivity and Mortality in Rheumatoid Arthritis and the Impact of Treatment With Disease-Modifying Antirheumatic Drugs: Results From a Real-World Study.
Alemao E; Bao Y; Weinblatt ME; Shadick N
Arthritis Care Res (Hoboken); 2020 Feb; 72(2):176-183. PubMed ID: 31529682
[TBL] [Abstract][Full Text] [Related]
10. Treatment of older adult patients diagnosed with rheumatoid arthritis: improved but not optimal.
Schmajuk G; Schneeweiss S; Katz JN; Weinblatt ME; Setoguchi S; Avorn J; Levin R; Solomon DH
Arthritis Rheum; 2007 Aug; 57(6):928-34. PubMed ID: 17665462
[TBL] [Abstract][Full Text] [Related]
11. Delay in initiation of DMARD or anti-inflammatory therapy in patients newly diagnosed with rheumatoid arthritis: An analysis of United States Military Health System TRICARE beneficiaries.
Kimsey L; Weissman JS; Patel A; Drew A; Koehlmoos T; Sparks JA
Semin Arthritis Rheum; 2019 Apr; 48(5):821-827. PubMed ID: 30190154
[TBL] [Abstract][Full Text] [Related]
12. Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register.
Dixon WG; Watson KD; Lunt M; Mercer LK; Hyrich KL; Symmons DP; ;
Arthritis Care Res (Hoboken); 2010 Jun; 62(6):755-63. PubMed ID: 20535785
[TBL] [Abstract][Full Text] [Related]
13. Validation of serostatus of rheumatoid arthritis using ICD-10 codes in administrative claims data.
Lee H; Sparks JA; Lee SB; Yoshida K; Landon JE; Kim SC
Pharmacoepidemiol Drug Saf; 2023 May; 32(5):586-591. PubMed ID: 36728737
[TBL] [Abstract][Full Text] [Related]
14. The effect of rheumatoid arthritis-associated autoantibodies on the incidence of cardiovascular events in a large inception cohort of early inflammatory arthritis.
Barra LJ; Pope JE; Hitchon C; Boire G; Schieir O; Lin D; Thorne CJ; Tin D; Keystone EC; Haraoui B; Jamal S; Bykerk VP;
Rheumatology (Oxford); 2017 May; 56(5):768-776. PubMed ID: 28073956
[TBL] [Abstract][Full Text] [Related]
15. Patient, disease, and therapy-related factors that influence discontinuation of disease-modifying antirheumatic drugs: a population-based incidence cohort of patients with rheumatoid arthritis.
Maradit-Kremers H; Nicola PJ; Crowson CS; O'Fallon WM; Gabriel SE
J Rheumatol; 2006 Feb; 33(2):248-55. PubMed ID: 16358365
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts.
van der Woude D; Young A; Jayakumar K; Mertens BJ; Toes RE; van der Heijde D; Huizinga TW; van der Helm-van Mil AH
Arthritis Rheum; 2009 Aug; 60(8):2262-71. PubMed ID: 19644846
[TBL] [Abstract][Full Text] [Related]
17. Databases of patients with early rheumatoid arthritis in the USA.
Sokka T; Willoughby J; Yazici Y; Pincus T
Clin Exp Rheumatol; 2003; 21(5 Suppl 31):S146-53. PubMed ID: 14969067
[TBL] [Abstract][Full Text] [Related]
18. Determinants of first-line biological treatment in patients with rheumatoid arthritis: Results from an observational study.
Angelici L; Addis A; Agabiti N; Kirchmayer U; Davoli M; Belleudi V
Medicine (Baltimore); 2021 May; 100(19):e25943. PubMed ID: 34106665
[TBL] [Abstract][Full Text] [Related]
19. The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis.
Chen HA; Lin KC; Chen CH; Liao HT; Wang HP; Chang HN; Tsai CY; Chou CT
Ann Rheum Dis; 2006 Jan; 65(1):35-9. PubMed ID: 15975966
[TBL] [Abstract][Full Text] [Related]
20. Association of anti-cyclic citrullinated peptide antibodies, anti-citrullin antibodies, and IgM and IgA rheumatoid factors with serological parameters of disease activity in rheumatoid arthritis.
Greiner A; Plischke H; Kellner H; Gruber R
Ann N Y Acad Sci; 2005 Jun; 1050():295-303. PubMed ID: 16014545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
